Compare ALGS & CXAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALGS | CXAI |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.6M | 27.8M |
| IPO Year | 2020 | 2020 |
| Metric | ALGS | CXAI |
|---|---|---|
| Price | $6.03 | $3.47 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $39.33 | N/A |
| AVG Volume (30 Days) | 127.4K | ★ 4.5M |
| Earning Date | 05-05-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.30 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $2,186,000.00 | ★ $4,583,000.00 |
| Revenue This Year | $32.20 | $33.54 |
| Revenue Next Year | $4.71 | $116.67 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.98 | $0.09 |
| 52 Week High | $13.69 | $4.88 |
| Indicator | ALGS | CXAI |
|---|---|---|
| Relative Strength Index (RSI) | 45.83 | 70.57 |
| Support Level | $4.80 | $0.21 |
| Resistance Level | $6.91 | $4.88 |
| Average True Range (ATR) | 0.56 | 0.37 |
| MACD | -0.12 | 0.07 |
| Stochastic Oscillator | 16.11 | 70.36 |
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
CXApp Inc is a provider of AI-powered employee experience solutions, delivering enterprise-grade software that enhances workplace engagement, productivity, and operational efficiency. Its cloud-based, mobile-first platform integrates artificial intelligence, automation, and real-time analytics to streamline workplace interactions across people, spaces, and technology. The company's flagship product, the CXAI Platform, provides a comprehensive suite of tools designed to empower employees and enable organizations to create smarter workplaces. The product's key components include CXAI Apps, CXAI BTS, Agentic AI Capabilities, and CXAI-VU. The company generates the majority of its revenue from Licenses.